AN2 Therapeutics Reports Q2 2026 Results, Extends Cash Runway into 2029, and Plans Three Phase 2 Programs by Year-End

summarizeSummary

AN2 Therapeutics reported Q2 2026 results with $79.9M in cash, a runway into 2029, and plans to have three Phase 2 programs active by year-end, including expanded PV trial sites and a new Chagas trial.

check_boxKey Events · Earnings and Guidance · ANTX

• Q2 2026 Financial Results

  The quarter produced a net loss of $8.2M, driven by R&D spend of $6.0M and G&A of $2.9M; cash, equivalents, and investments stood at $79.9M as of June 30, 2026.

• Cash Runway Extended to 2029

  Under the current operating plan, management projects that existing cash will fund operations into 2029, reducing near-term dilution risk.

• Three Phase 2 Programs by Year-End

  Epetraborole's Phase 2 in PV is expanding to the U.S. and Australia, with an IND filing in Q3 and enrollment in Q4 2026; an investigator-initiated Phase 2 in M. abscessus is ongoing; and a Phase 2 trial of AN2-502998 in chronic Chagas is expected to begin late 2026.

• Pipeline Expansion

  A second boron-based development candidate is expected by the end of 2026, following the ENPP1 candidate for solid tumors declared earlier this year.

auto_awesomeAnalysis · ANTX · Life Sciences

AN2 Therapeutics disclosed Q2 2026 financials, posting a net loss of $8.2 million and holding $79.9 million in cash, which extends its runway into 2029. The company is advancing three Phase 2 programs — epetraborole in polycythemia vera and M. abscessus, and AN2-502998 in chronic Chagas — with enrollment milestones in 2026 and data readouts in 2027. While the pipeline expansion and extended cash runway reduce near-term financing risk, the stock remains under pressure from prior dilutive financings.